Literature DB >> 3856324

Molecular cloning of the complementary DNA for human tumor necrosis factor.

A M Wang, A A Creasey, M B Ladner, L S Lin, J Strickler, J N Van Arsdell, R Yamamoto, D F Mark.   

Abstract

Tumor necrosis factor (TNF) is a soluble protein that causes damage to tumor cells but has no effect on normal cells. Human TNF was purified to apparent homogeneity as a 17.3-kilodalton protein from HL-60 leukemia cells and showed cytotoxic and cytostatic activities against various human tumor cell lines. The amino acid sequence was determined for the amino terminal end of the purified protein, and oligodeoxyribonucleotide probes were synthesized on the basis of this sequence. Complementary DNA (cDNA) encoding human TNF was cloned from induced HL-60 messenger RNA and was confirmed by hybrid-selection assay, direct expression in COS-7 cells, and nucleotide sequence analysis. The human TNF cDNA is 1585 base pairs in length and encodes a protein of 233 amino acids. The mature protein begins at residue 77, leaving a long leader sequence of 76 amino acids. Expression of high levels of human TNF in Escherichia coli was accomplished under control of the bacteriophage lambda PL promoter and gene N ribosome binding site.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3856324     DOI: 10.1126/science.3856324

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  150 in total

1.  Improving the binding affinity of an antibody using molecular modeling and site-directed mutagenesis.

Authors:  C L Casipit; R Tal; V Wittman; P A Chavaillaz; K Arbuthnott; J A Weidanz; J A Jiao; H C Wong
Journal:  Protein Sci       Date:  1998-08       Impact factor: 6.725

Review 2.  DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors.

Authors:  P D'Orléans-Juste; M G Sirois; E R Edelman; D Regoli; L H Pheng; G Bkaily; C J Lindsey
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

3.  Hierarchy of in vitro sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs and toxins.

Authors:  J T Safrit; B Bonavida
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Primary structure of ovine tumor necrosis factor alpha cDNA.

Authors:  A J Young; J B Hay; J Y Chan
Journal:  Nucleic Acids Res       Date:  1990-11-25       Impact factor: 16.971

5.  Ocular inflammatory effects of intravitreally-injected tumor necrosis factor.

Authors:  J T Rosenbaum; E L Howes; R M Rubin; J R Samples
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

6.  Recombinant interleukin-1 alpha and recombinant tumor necrosis factor alpha synergize in vivo to induce early endotoxin tolerance and associated hematopoietic changes.

Authors:  S N Vogel; E N Kaufman; M D Tate; R Neta
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

7.  Destruction of tumor cells by monokines released from activated human blood monocytes: evidence for parallel and additive effects of IL-1 and TNF.

Authors:  Y Ichinose; J Y Tsao; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Human tumor necrosis factor increases the resistance against Listeria infection in mice.

Authors:  K Kato; A Nakane; T Minagawa; N Kasai; K Yamamoto; N Sato; N Tsuruoka
Journal:  Med Microbiol Immunol       Date:  1989       Impact factor: 3.402

9.  Presence of tumour necrosis factor or a related factor in human basophil/mast cells.

Authors:  M Steffen; M Abboud; G K Potter; Y P Yung; M A Moore
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

10.  Antimetastatic effect of endogenous tumor necrosis factor induced by the treatment of recombinant interferon gamma followed by an analogue (GLA-60) to synthetic lipid A subunit.

Authors:  I Saiki; H Maeda; J Murata; N Yamamoto; M Kiso; A Hasegawa; I Azuma
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.